Wanbury Limited has informed the Exchange regarding a press release dated October 16, 2026, titled "Wanbury Limited Regulatory Progress in API Business, New Business Opportunities and Operational Achievements".

Summary by 6ix AI

Wanbury Limited has issued a press release detailing its regulatory progress in the API business, including new opportunities and operational achievements. The company received multiple 'No DMF Deficiency' letters from the USFDA, affirming the quality of its regulatory filings and opening new business avenues. Additionally, Wanbury is expanding its API portfolio and has commercialized a new Metformin business in Saudi Arabia, along with securing a tender in Mexico. These developments position Wanbury for sustained growth in the global market.

Written by 6ix AI from the company’s filing. How 6ix writes summaries